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The lantibiotics are a class of polycyclic peptide natural products
that exhibit antimicrobial activity against a variety of clinically
relevant bacterial pathogens.
1,2 These compounds have a long
history of use in food preservation and possess considerable promise
as human therapeutics because of their potency and unique modes
of action.
3 Lantibiotics are ribosomally synthesized as linear
prepeptides and are extensively post-translationally modiﬁed to their
active forms. These modiﬁcations introduce thioether-containing
cross-linked amino acids called lanthionine (Lan) and methyl-
lanthionine (MeLan) as well as dehydroalanine (Dha) and dehy-
drobutyrine (Dhb) residues. The latter motifs result from enzymatic
dehydration of Ser or Thr residues, respectively. (Me)Lan cross-
links are then installed through enzymatic intramolecular Michael-
type addition of Cys thiols onto the unsaturated amino acids. Despite
their potential as antimicrobial therapeutics, signiﬁcant hurdles must
be overcome for lantibiotics to reach the clinic, including improving
the solubility and stability of the compounds under physiological
conditions.
The generation of lantibiotic analogues for structure-activity
studies has traditionally been conducted through in vivo mutagenesis
of lantibiotic prepeptides. Such studies have provided a wealth of
knowledge regarding lantibiotic structure-activity relationships but
have yielded only a few lantibiotics with enhanced bioactivity
4 or
improved therapeutic properties.
5 The chemical synthesis of lan-
tibiotics has been achieved for two family members.
6,7 In principle,
synthesis provides access to lantibiotic analogues with expanded
chemical diversity by introduction of nonproteinogenic amino acids.
At present, however, no such analogues have been reported. An
alternative approach is to use biosynthetic enzymes with synthetic
substrate analogues, a strategy we term in vitro mutasynthesis
(IVM). We report herein the ﬁrst preparation of lantibiotic analogues
containing nonproteinogenic amino acids using IVM. Several of
these analogues possess improved antimicrobial activity.
Lacticin 481 is a lantibiotic produced by Lactococcus lactis
CNRZ 481 that contains three Me(Lan) rings and one Dhb residue.
8
Lacticin 481 synthetase (LctM) introduces these post-translational
modiﬁcations by catalyzing both dehydration and cyclization of
its substrate prepeptide, LctA.
9 LctA is a 51 amino acid peptide
consisting of a C-terminal structural peptide that undergoes post-
translational modiﬁcation as well as an N-terminal leader peptide
that is required for efﬁcient processing by LctM.
10,11 Several recent
reports have characterized the promiscuous substrate speciﬁcity of
LctM toward truncated LctA mutant substrates.
12-14 A signiﬁcant
challenge for the introduction of nonproteinogenic amino acids into
lacticin 481 is the preparation of full-length LctA prepeptides. For
this purpose, we developed the synthesis of a triazole-linked LctA
peptide analogue (3) via Cu(I)-catalyzed 1,3-dipolar cycloaddition
of an alkyne-functionalized LctA leader peptide (1) and an azide-
modiﬁed LctA structural region (2).
14 This strategy was utilized
here to prepare triazole-linked LctA substrates containing several
nonproteinogenic amino acids in the structural peptide, including
 -amino acids, D-amino acids, and N-alkylglycine (peptoid) resi-
dues. An additional two mutations, Asn15Arg and Phe21His, were
included in substrate 3 to improve solubility.
15,16 On the basis of
our previous survey of the types of amino acids that are tolerated
by LctM,
14 substrates including the following nonproteinogenic
amino acid mutations were prepared (Figure 1): sarcosine (Sar) and
aminocyclopropanoic acid (Acpc) in place of Gly5, D-valine at
position 6, 4-cyanoaminobutyric acid (Cba) in place of Glu13,  3-
homoarginine ( 3-Arg) at position 15, N-butylglycine (N-Nle) and
 -Ala replacing Met16, naphthylalanine (Nal) at Trp19, 4-pyridy-
nylalanine (Pal) at position 21, and homophenylalanine (hPhe) in
place of Phe23. A ﬁnal analogue contained three concomitant
replacements of Gly2, Gly3, and Gly5 with  -Ala. The triazole-
linked LctA substrate analogues (0.5-1.5 mg) were incubated with
0.5 µM LctM in the presence of 10 mM Mg2+ and 1 mM ATP.
Assay progress was monitored by MALDI-TOF MS. Each of the
unnatural LctA substrates was dehydrated four times by LctM, as
shown for representative examples in Figure 2 (all of the MS data
is provided in the Supporting Information). Typically, a small
amount of threefold-dehydrated product was also present and readily
removed via reversed-phase HPLC. To produce bioactive lacticin
481 analogues, the leader peptide and triazole linker were removed
Figure 1. In vitro mutasynthesis of lacticin 481 analogues. Synthetic
substrate analogues were prepared using copper-catalyzed [2 + 3] cycload-
dition of two fragment peptides. The resulting LctA analogues were treated
with LctM, which dehydrated the underlined Ser and Thr residues and
incorporated the thioether rings shown. Mutant analogues generated are
indicated with arrows. Lan residues are shown in red, and the MeLan cross-
link is shown in blue.
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which efﬁciently cleaved the modiﬁed substrates C-terminal to
Lys1.
16 Thus, lacticin 481 analogues were produced in high purity
(Figure S4 in the Supporting Information). To ensure that complete
cyclization had occurred, the analogues were incubated with a thiol-
modifying reagent, demonstrating that no free thiols remained in
the LctM-treated peptides.
The bioactivity of the analogues was evaluated by agar diffusion
assays against the indicator strain L. lactis HP (Figure 3). The
analogues and the parent compound (4) that did not contain any
nonproteinogenic amino acids were spotted against L. lactis HP in
a 96-well format. For initial characterization, each compound was
spotted and the zone of inhibition measured following overnight
incubation. Three of the lacticin 481 analogues, the ones containing
Trp19Nal, Phe21Pal, and Phe23hPhe mutations, provided zones of
inhibition larger than the parent compound 4, as shown in Figure
3. The Gly5Sar, Gly5Acpc, Met16 -Ala, and Asn15 3-Arg mutant
lantibiotics displayed a signiﬁcant decrease in activity (∼16-34
fold; see Figure S6), while the Glu13Cba, Met16N-Nle, and Val6D-
Val mutants as well as the analogue with three concomitant  -Ala
mutations displayed no bioactivity within the limits of the assay.
The compounds containing Trp19Nal, Phe21Pal, and Phe23hPhe
mutations were also tested against Bacillus subtilis ATCC 6633
and provided trends in activity analogous to those observed with
L. lactis HP (Figure S7). Minimum inhibitory concentration (MIC)
values were determined against L. lactis HP for the three variants
with improved activity in the agar diffusion assay. The obtained
MIC values were 3.12 µM for Trp19Nal and Phe23hPhe, compared
with 6.25 µM for the parent 4 and 12.5 µM for Phe21Pal; the
improved agar diffusion activity for the latter compound may have
been the result of differential diffusion rates.
The results presented here provide guidelines for further engi-
neering. For example, the two analogues with improved bioactivity
each contained nonproteinogenic amino acid substitutions in the
C-ring of lacticin 481, suggesting this region as a site for additional
mutation. Furthermore, each of these analogues contained non-
natural side-chain substituents, whereas analogues with an altered
amide backbone ( -amino acids or peptoids) had diminished
activity. Finally, a dramatic decrease in activity was noted with all
mutants containing substitutions in the N-terminal residues of
lacticin 481.
In summary, we have presented the ﬁrst preparation of lantibiotic
analogues containing nonproteinogenic amino acids, suggesting that
in vitro engineering of lantibiotics can be a viable method for
identifying improved bioactive compounds.
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Figure 2. Representative MALDI-MS spectra after incubation of triazole-
linked LctA substrate analogues (3, blue) with LctM in the presence of
ATP and Mg2+ (red). Asterisks represent threefold-dehydrated products.
Figure 3. Antimicrobial assays for biological activity of selected lacticin
481 analogues against L. lactis HP.
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